scholarly article | Q13442814 |
P50 | author | Leonard B. Kaban | Q6525086 |
Zachary S Peacock | Q89344252 | ||
Soldano Ferrone | Q90626068 | ||
P2093 | author name string | Francis J Hornicek | |
Joseph H Schwab | |||
Ahmad Al-Sukaini | |||
P2860 | cites work | Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone | Q24595521 |
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
Cancer immunotherapy: the beginning of the end of cancer? | Q26752277 | ||
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells | Q26866479 | ||
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
Do Histologic Criteria Predict Biologic Behavior of Giant Cell Lesions? | Q61822198 | ||
Maxillofacial and Axial/Appendicular Giant Cell Lesions: Unique Tumors or Variants of the Same Disease?—A Comparison of Phenotypic, Clinical, and Radiographic Characteristics | Q61822207 | ||
A system of staging musculoskeletal neoplasms | Q68720907 | ||
Central giant cell lesions of the jaws: a clinicopathologic study | Q68734854 | ||
Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products | Q69621634 | ||
Lymphocyte in vitro response to human giant cell tumors | Q71056736 | ||
High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress | Q73373427 | ||
Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients | Q79101785 | ||
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy | Q80767732 | ||
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone | Q28066533 | ||
Cancer immunoediting: from immunosurveillance to tumor escape | Q28212251 | ||
Giant cell tumor of bone: treatment and outcome of 214 cases | Q28271725 | ||
12th International Histocompatibility Conference. Genetic diversity of HLA: functional and medical implications. Paris, France, June 9-12, 1996. Abstracts | Q28296026 | ||
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 | Q29622893 | ||
The origin of the neoplastic stromal cell in giant cell tumor of bone | Q30164416 | ||
Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide | Q31152009 | ||
The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). | Q33765607 | ||
Antigen-processing machinery breakdown and tumor growth | Q34011098 | ||
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction | Q34298906 | ||
B7-h3 and its role in antitumor immunity | Q34356712 | ||
Properties of the stromal cell in giant cell tumor of bone | Q34576537 | ||
B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis | Q34935785 | ||
Genetic Analysis of Giant Cell Lesions of the Maxillofacial and Axial/Appendicular Skeletons | Q36108604 | ||
Cancer immunotherapy: Strategies for personalization and combinatorial approaches | Q36387028 | ||
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial | Q36929714 | ||
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance | Q37287152 | ||
Clinical importance of B7-H3 expression in human pancreatic cancer | Q37424100 | ||
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma | Q37461786 | ||
B7-H3 and its relevance in cancer; immunological and non-immunological perspectives | Q37881559 | ||
B7-H3-mediated tumor immunology: Friend or foe? | Q38135281 | ||
Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968 | Q39222074 | ||
Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response | Q39274136 | ||
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity | Q39344502 | ||
Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens | Q39572530 | ||
Adjuvant Antiangiogenic Treatment for Aggressive Giant Cell Lesions of the Jaw: A 20-Year Experience at Massachusetts General Hospital | Q39619726 | ||
Adjuvant antiangiogenic therapy for giant cell tumors of the jaws | Q40438612 | ||
Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. | Q41018967 | ||
Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues | Q41552807 | ||
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy | Q41809391 | ||
Cancer immunotherapy trials: leading a paradigm shift in drug development | Q42414063 | ||
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases | Q43136029 | ||
Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. | Q44788378 | ||
Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3. | Q46739835 | ||
At the crossroads of cancer | Q46800604 | ||
The highly prevalent H3F3A mutation in giant cell tumours of bone is not shared by sporadic central giant cell lesion of the jaws. | Q54183171 | ||
A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. | Q54324671 | ||
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. | Q54339544 | ||
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone | Q57570810 | ||
P407 | language of work or name | English | Q1860 |
P577 | publication date | 2017-07-19 | |
P1433 | published in | Clinical Orthopaedics and Related Research | Q5133783 |
P1476 | title | Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone |
Q52561316 | Letter to the Editor: Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. |
Q90326654 | Profiling targetable immune checkpoints in osteosarcoma |
Q88482675 | Reply to the Letter to the Editor: Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone |
Q54974872 | STAT1, IGF1, RAC1, and MDM2 Are Associated with Recurrence of Giant Cell Tumor of Bone. |
Search more.